1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CC15E6D84FAE6B208525828A006BABAA
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/value-relationships-with-external-groups-specialty-pharmacies-group-purchasing-organizations-pathway-vendors-large-employer-groups?opendocument
18
19opendocument
2018.97.14.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Affairs Excellence

How Medical Affairs Creates Value & Relationships with External Groups: Specialty Pharmacies, Group Purchasing Organizations, Pathway Vendors, & Large Employer Groups

ID: 5510


Features:

11 Info Graphics

25 Data Graphics

400+ Metrics


Pages/Slides: 49


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "How Medical Affairs Creates Value & Relationships with External Groups: Specialty Pharmacies, Group Purchasing Organizations, Pathway Vendors and Large Employer Groups"

STUDY OVERVIEW


A constantly evolving healthcare landscape has pushed Medical Affairs groups to interact with an ever-expanding list of external groups. As a result, Medical Affairs leaders are continually adjusting what external groups they work with and how they work with them. And as emerging groups such as specialty pharmacies, GPOs, and pathway vendors have become important players in the critical access and reimbursement arena, Medical Affairs is now providing medical support to these organizations.


But with these groups a relatively new customer for Medical Affairs, organizations are still working out which functions and activities resonate best with these emerging groups. Best Practices, LLC performed this research study to probe Medical Affairs' roles, tools, effectiveness and success metrics in serving specialty pharmacies, GPOs, large employers and pathway vendors.

This study will help Medical Affairs leaders identify the tools, activities, services that peers are utilizing to meet the needs of these organizations. It also provides key performance indicators and best practices to demonstrate value to them.


KEY TOPICS

  • Executive Summary
  • Interactions with External Groups
  • Specialized Tools, Roles, Services and Involvement Timeline with specialty pharmacies and other emerging groups
  • Changing Policies, Activities and KPIs of Medical Affairs to Work with specialty pharmacies and other emerging groups
  • Global Standards, Best Practices and Challenges

SAMPLE KEY METRICS

  • What external groups does your Medical Affairs organization work with
  • How important are these external groups to your Medical Affairs organization
  • How effective is your Medical Affairs organization's work with these external groups
  • Which functions within your Medical Affairs organization have a role with specialty pharmacies, GPOs, large employers and pathway vendors
  • What tools does your Medical Affairs organization use to showcase value to specialty pharmacies, GPOs, large employers and pathway vendors
  • Rate the effectiveness of these tools used with specialty pharmacies, GPOs, large employers and pathway vendors
  • What are your key performance indicators for working with specialty pharmacies, GPOs, large employers and pathway vendors
  • What activities does your Medical Affairs organization conduct with specialty pharmacies, GPOs, large employers and pathway vendors

SAMPLE KEY FINDING

  • Timeline of Interactions: The importance of Specialty Pharmacies picks up during the launch with 93% of respondents rating Specialty Pharmacies very important. During the pre-launch and brand building 50% and 64% of respondents rated Specialty Pharmacies very important. Once the product reaches maturity, the importance of working with Specialty Pharmacies dips to only 21%.

METHODOLOGY


For this research, Best Practices, LLC engaged 50 Medical Affairs experts at 33 companies through a benchmarking survey. Research participants include Chief Medical Officer (CMO), VPs, Heads, Directors, Managers/Leaders and Specialists.


Industries Profiled:
Biotech; Chemical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Communications


Companies Profiled:
Genentech; Boehringer Ingelheim; Novartis; EMD Serono; Bayer; Roche; Amgen; Novo Nordisk; Astellas; Shire; Abbott; Pfizer; Sanofi; Sandoz; Takeda Pharmaceuticals; Santen; Vifor Pharma; cipla; Siemens Healthcare; UCB Pharma; Roche Diagnostics; Teva Pharmaceutical Industries Ltd; Sanofi Genzyme; Jazz Pharmaceuticals; Janssen; Ferring Pharmaceuticals; Upsher-Smith; Seattle Genetics; Otonomy; CSL Behring; Sunovion; Tillotts Pharma; ApotheCom

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.